![](/img/cover-not-exists.png)
Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
Tan, A. R., Rubin, E. H., Walton, D. C., Shuster, D. E., Wong, Y. N., Fang, F., Ashworth, S., Rosen, L. S.Volume:
15
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-09-0360
Date:
June, 2009
File:
PDF, 208 KB
english, 2009